ECSP22016924A - Un método para preparar ivosidenib y un intermediario del mismo - Google Patents

Un método para preparar ivosidenib y un intermediario del mismo

Info

Publication number
ECSP22016924A
ECSP22016924A ECSENADI202216924A ECDI202216924A ECSP22016924A EC SP22016924 A ECSP22016924 A EC SP22016924A EC SENADI202216924 A ECSENADI202216924 A EC SENADI202216924A EC DI202216924 A ECDI202216924 A EC DI202216924A EC SP22016924 A ECSP22016924 A EC SP22016924A
Authority
EC
Ecuador
Prior art keywords
ivosidenib
preparing
synthesize
application relates
current application
Prior art date
Application number
ECSENADI202216924A
Other languages
English (en)
Spanish (es)
Inventor
Shijie Zhang
Nha Vo
Jacob Sizemore
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of ECSP22016924A publication Critical patent/ECSP22016924A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
ECSENADI202216924A 2019-08-08 2022-03-07 Un método para preparar ivosidenib y un intermediario del mismo ECSP22016924A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962884480P 2019-08-08 2019-08-08

Publications (1)

Publication Number Publication Date
ECSP22016924A true ECSP22016924A (es) 2022-06-30

Family

ID=74504162

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202216924A ECSP22016924A (es) 2019-08-08 2022-03-07 Un método para preparar ivosidenib y un intermediario del mismo

Country Status (33)

Country Link
US (1) US12479824B2 (pl)
EP (1) EP4010331B1 (pl)
JP (1) JP7644747B2 (pl)
KR (1) KR20220061971A (pl)
CN (1) CN114555584B (pl)
AU (1) AU2020327013A1 (pl)
BR (1) BR112022002253A2 (pl)
CA (1) CA3150028A1 (pl)
CL (1) CL2022000310A1 (pl)
CO (1) CO2022001991A2 (pl)
CR (1) CR20220090A (pl)
DK (1) DK4010331T3 (pl)
EC (1) ECSP22016924A (pl)
ES (1) ES2967909T3 (pl)
FI (1) FI4010331T3 (pl)
GE (2) GEAP202415882A (pl)
HR (1) HRP20231618T1 (pl)
HU (1) HUE064193T2 (pl)
IL (1) IL290377B2 (pl)
LT (1) LT4010331T (pl)
MA (1) MA56783B1 (pl)
MD (1) MD4010331T2 (pl)
MX (1) MX2022001619A (pl)
MY (1) MY207344A (pl)
PE (1) PE20221761A1 (pl)
PH (1) PH12022550266A1 (pl)
PL (1) PL4010331T3 (pl)
PT (1) PT4010331T (pl)
RS (1) RS64934B1 (pl)
SI (1) SI4010331T1 (pl)
SM (1) SMT202300489T1 (pl)
TW (1) TWI890687B (pl)
WO (1) WO2021026436A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
ES2378473T3 (es) 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
CN106795146B (zh) 2014-10-01 2020-06-26 第一三共株式会社 作为突变型异柠檬酸脱氢酶1抑制剂的异噁唑衍生物
WO2019104318A1 (en) * 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ivosidenib
US12264148B2 (en) * 2018-07-06 2025-04-01 Servier Pharmaceuticals Llc Ivosidenib forms and pharmaceutical compositions
WO2020127887A1 (en) * 2018-12-21 2020-06-25 Sandoz Ag Process for the preparation of an intermediate product of ivosidenib

Also Published As

Publication number Publication date
PE20221761A1 (es) 2022-11-11
CO2022001991A2 (es) 2022-07-29
MY207344A (en) 2025-02-20
IL290377B2 (en) 2025-04-01
KR20220061971A (ko) 2022-05-13
ES2967909T3 (es) 2024-05-06
US12479824B2 (en) 2025-11-25
CA3150028A1 (en) 2021-02-11
PT4010331T (pt) 2024-01-08
TW202120491A (zh) 2021-06-01
IL290377A (en) 2022-04-01
MA56783B1 (fr) 2023-10-31
SMT202300489T1 (it) 2024-01-10
EP4010331A1 (en) 2022-06-15
US20230025411A1 (en) 2023-01-26
GEP20247709B (en) 2024-12-25
IL290377B1 (en) 2024-12-01
SI4010331T1 (sl) 2024-02-29
DK4010331T3 (da) 2023-12-18
HUE064193T2 (hu) 2024-02-28
CR20220090A (es) 2022-08-24
WO2021026436A1 (en) 2021-02-11
CL2022000310A1 (es) 2022-11-25
CN114555584B (zh) 2024-07-05
JP7644747B2 (ja) 2025-03-12
EP4010331B1 (en) 2023-10-04
LT4010331T (lt) 2023-11-10
FI4010331T3 (fi) 2023-12-28
JP2022544143A (ja) 2022-10-17
MD4010331T2 (ro) 2024-03-31
PH12022550266A1 (en) 2022-11-21
GEAP202415882A (en) 2024-08-12
PL4010331T3 (pl) 2024-03-11
RS64934B1 (sr) 2023-12-29
HRP20231618T1 (hr) 2024-03-15
AU2020327013A1 (en) 2022-03-24
MX2022001619A (es) 2022-07-19
CN114555584A (zh) 2022-05-27
TWI890687B (zh) 2025-07-21
BR112022002253A2 (pt) 2022-07-05

Similar Documents

Publication Publication Date Title
AU2019222480A8 (en) Improved yeast for ethanol production
WO2022192414A3 (en) Synthesis of omecamtiv mecarbil
AR109393A1 (es) Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
CO2021014022A2 (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
BR112022011946A2 (pt) Derivado de triazolopiridazina, método de preparação para o mesmo, composição farmacêutica do mesmo, e uso do mesmo
ZA202305214B (en) Method for preparing l-glufosinate
EA202091979A1 (ru) Кристаллические формы и способы получения кристаллических форм соединения
CO2020012574A2 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
CL2022000492A1 (es) Proceso para la preparación de estetrol de alta pureza.
WO2019224713A3 (en) Monospecific and multispecific anti-tmeff2 antibodies and there uses
EP4007809A4 (en) NK-92 CELLS MODIFIED BY CHIMERIC ANTI-B7-H4 ANTIGEN RECEPTOR
MX2020004869A (es) Metodo para preparar derivado de benzofurano.
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
ECSP22016924A (es) Un método para preparar ivosidenib y un intermediario del mismo
MX2024011469A (es) Metodo y compuesto utiles en la preparacion del antagonista del receptor de orexina-2 y lemborexant que tiene pocas impurezas.
EP3769413A4 (en) STRUCTURAL BEAM FOR SUN FOLLOWERS
CO2024000763A2 (es) Composiciones y métodos de los anticuerpos anti-pacap
EP4552691A3 (en) Preparation of trifarotene and intermediates and polymorphs thereof
EP3795556A4 (en) PROCESS FOR DIRECT PREPARATION OF DIMETHYL ETHER BY SYNTHESIS GAS
MX2022002563A (es) Nuevo promotor y metodo para producir la sustancia deseada usando el mismo.
CL2024003050A1 (es) Método e intermediario para la preparación de apalutamida.
CO2022009062A2 (es) Composición para la preparación de alulosa y procedimiento para la preparación de alulosa mediante el uso de la misma
WO2021022111A3 (en) β-ARRESTIN-MODULATING COMPOUNDS AND METHODS OF USING SAME
CR20220153A (es) Derivados de 2–azaespiro [3.4] octano como agonistas de m4
PH12020551233A1 (en) Water soluble salts of lipidated peptides and methods for preparing and using the same